Table 3.

Adverse events^a

Term	All grades	Grade 3	Grade 4
	n (%)
Patients with at least one adverse event	65 (92.9)	13 (18.6)	2 (2.9)
Hematologic events
Leukopeniab	13 (18.6)	0	0
Neutropeniac	10 (14.3)	1 (1.4)	0
Thrombocytopeniad	8 (11.4)	0	1 (1.4)
Anemia	7 (10)	0	0
Nonhematologic events
Pyrexia	38 (54.3)	0	0
Hypothyroidism	23 (32.9)	0	0
Weight gain	21 (30)	0	0
Upper respiratory tract infection	21 (30)	2 (2.9)	0
Cough	12 (17.1)	0	0
Pruritus	12 (17.1)	0	0
Rash	9 (12.9)	1 (1.4)	0
Alanine aminotransferase increased	9 (12.9)	0	0
Diarrhea	7 (10)	0	0
Aspartate aminotransferase increased	7 (10)	0	0
Hyperuricemia	6 (8.6)	0	0
Weight loss	6 (8.6)	0	0
Asthenia	5 (7.1)	0	0
Blood bilirubin increased	5 (7.1)	0	0
Headache	5 (7.1)	0	0
Hyperlipidemia	5 (7.1)	0	0
Pain in extremity	5 (7.1)	0	0
Chills	4 (5.7)	0	0
Influenza	4 (5.7)	0	0
Lung infection	4 (5.7)	0	0
Nausea	4 (5.7)	0	0
Back pain	4 (5.7)	1 (1.4)	0
Viral upper respiratory tract infection	4 (5.7)	0	0
Vomiting	4 (5.7)	0	0

^aData are for adverse events reported during treatment in the 70 patients included in the study. Listed events occurred in at least 5% of patients or two or more for grade 3 and any events for grade 4 on or before the data cutoff date of July 23, 2018

^bIncludes the MedDRA preferred terms, leukopenia and white blood cell count decreased

^cIncludes the MedDRA preferred terms, neutropenia and neutrophil count decreased

^dIncludes the MedDRA preferred terms, thrombocytopenia and platelet count decreased.